Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. (symbol: VTGN) is a pioneering biotechnology firm committed to improving the lives of patients with central nervous system (CNS) disorders. The company leverages its advanced stem cell technology platform, which is based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed human cells. This innovative platform enables the creation of novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue, and cell therapy, providing clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
At the clinical stage, Vistagen is actively involved in developing and commercializing a robust pipeline consisting of six product candidates. Five of these candidates are clinical-stage investigational agents known as pherines, which represent a new class of drugs. Notable products within their portfolio include:
- PH94B: A novel neuroactive nasal spray designed to treat social anxiety disorder.
- PH10: An odorless, fast-acting synthetic neurosteroid aimed at addressing major depressive disorder (MDD).
- AV-101: An oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR), which is being developed to treat MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy.
Vistagen's innovative approach and dedication to CNS disorders position it as a significant player in the biotechnology sector. The company is continually making strides in its research and clinical trials, striving to bring groundbreaking therapies to market. Investors and stakeholders can look forward to Vistagen's ongoing developments and potential future successes as it targets unmet medical needs with its cutting-edge technologies and therapeutic candidates.
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) has regained compliance with Nasdaq's minimum bid price requirement as of January 5, 2021. The company previously received a notice on January 31, 2020, regarding non-compliance due to a bid price below $1.00 for 30 consecutive business days. VistaGen met the requirement by maintaining a closing bid price of $1.00 or more for 10 consecutive trading days, starting January 4, 2021. VistaGen is now compliant with all Nasdaq listing standards, and the matter is considered closed by Nasdaq.
VistaGen Therapeutics (NASDAQ: VTGN) announced the publication of an article by Dr. Louis Monti and Dr. Michael Liebowitz in CNS Spectrums, detailing the mechanism of action of its investigational neuroactive nasal sprays, PH94B and PH10. These drugs aim to provide rapid-onset treatments for anxiety and depression, respectively, with microgram-level doses designed to avoid the typical side effects of current medications. VistaGen is preparing PH94B for Phase 3 studies and has received Fast Track designation from the FDA.
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) has successfully closed a $100 million public offering, selling 63 million shares of common stock at $0.92 each and 2 million shares of Series D preferred stock at $21.16 each. The Series D shares can convert into common stock pending shareholder approval for a necessary increase in authorized shares. Proceeds will support research, development, and regulatory expenses for CNS drug candidates such as PH94B and AV-101, alongside general corporate needs.
VistaGen Therapeutics (NASDAQ: VTGN) has announced a public offering of 63 million shares of common stock at $0.92 each and 2 million shares of Series D preferred stock at $21.16 each, aiming to raise approximately $100 million. The proceeds will support the development of its CNS drug candidates, including PH94B and PH10, as well as other operational costs. The offering is expected to close by December 22, 2020, pending standard conditions. The securities are registered under a previously filed shelf registration statement with the SEC.
VistaGen Therapeutics (NASDAQ: VTGN) announced a public offering of units comprising common stock and Series D convertible preferred stock. The offering, subject to market conditions, aims to raise capital for research and development of its CNS drug candidates, including PH94B, PH10, and AV-101. The preferred stock can convert into common stock pending stockholder approval to increase authorized shares. The company intends to use the proceeds for ongoing clinical and manufacturing expenses, as well as for general corporate purposes.
VistaGen Therapeutics (NASDAQ: VTGN) announced a significant milestone with the Korean Intellectual Property Office granting a patent for PH10, a nasal spray designed to treat major depressive disorder (MDD). This patent extends protection until at least 2034 and complements existing patents in multiple regions including the U.S. and Europe. CEO Shawn K. Singh emphasized that this patent strengthens their global strategy for PH10, especially as MDD impacts over 264 million adults globally, underscoring the urgent need for innovative treatment options.
VistaGen Therapeutics (NASDAQ: VTGN) has appointed Louis Monti, M.D., Ph.D., as Vice President of Translational Medicine, expanding its R&D team. Dr. Monti has worked with the company since 2018 on drug candidates PH94B and PH10, designed to treat anxiety and depression. PH94B has received FDA Fast Track designation and is preparing for Phase 3 trials for social anxiety disorder (SAD). PH10 is set for Phase 2B development for major depressive disorder (MDD). Both candidates show potential as rapid-onset treatments, which could revolutionize the management of these mental health disorders.
VistaGen Therapeutics (NASDAQ: VTGN) reported its fiscal 2021 Q2 financial results for the quarter ending September 30, 2020. The company demonstrated a reduced net loss of approximately $3.7 million, down from $5.7 million in the prior year. Revenue for the quarter was $334,000 associated with a $5 million upfront license payment from EverInsight Therapeutics. R&D expenses decreased significantly to $2.4 million, reflecting the completion of previous clinical studies. VistaGen is advancing its CNS pipeline, preparing for a pivotal Phase 3 study of PH94B for social anxiety disorder set to launch in Q2 2021.
VistaGen Therapeutics (NASDAQ: VTGN) announced new in vitro data showing that PH94B, an intranasal treatment for social anxiety disorder, does not activate GABA-A receptors, differentiating it from benzodiazepines. This suggests that PH94B may avoid common side effects, such as sedation and addiction, making it a safer alternative for treating anxiety. With the FDA's Fast Track designation for PH94B, the company aims to address rising anxiety disorders exacerbated by current societal stressors, moving towards pivotal Phase 3 development.
VistaGen Therapeutics (NASDAQ: VTGN) announced participation in the Guggenheim Healthcare Talks, specifically at the 2nd Annual Neuro/Immunology Day on November 16, 2020. This virtual event will focus on neurological and immunological diseases, highlighting both established and emerging companies. VistaGen is dedicated to developing innovative treatments for anxiety, depression, and other CNS disorders, and is committed to exceeding current treatment standards. For more details, visit www.vistagen.com.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
What does Vistagen Therapeutics, Inc. specialize in?
What is the company's main technological focus?
What are pherines?
Can you name some of Vistagen Therapeutics' key products?
What is PH94B used for?
What is PH10?
What conditions is AV-101 aimed at treating?
How does Vistagen's stem cell technology benefit drug development?
Is Vistagen Therapeutics currently in the clinical stage?
Where can I find the latest news about Vistagen Therapeutics, Inc.?
